Newsroom

November 2018

• 
  Story Nov 26, 2018 From Our Labs

  Reimagining protein sequencing

  Three years after discussing how to reuse an old scientific measuring device, Novartis scientists are now testing this idea as part of an innovative research project.

• Press release Nov 23, 2018

  Novartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal disease

  Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65…
• Press release Nov 20, 2018

  Novartis rises to second place in 2018 Access to Medicine Index

  Company leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in…
• Press release Nov 20, 2018

  Sandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use Disorder

  reSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…
• Press release Nov 16, 2018

  FDA approves Novartis drug Promacta® for first-line SAA and grants Breakthrough Therapy designation for additional new indication

  Promacta receives FDA approval for first-line treatment of severe aplastic anemia (SAA) and Breakthrough Therapy designation for low platelet counts in people exposed to radiation  Approval…
• Press release Nov 16, 2018

  Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer

  Kisqali is the CDK4/6 inhibitor with the largest body of first-line evidence demonstrating consistent, superior and sustained efficacy vs. endocrine therapy alone[1]   CHMP opinion is…
• Ad hoc release Nov 13, 2018

  Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London

  Basel, November 13, 2018 - Novartis today announced that Alcon has filed an initial Form 20-F registration statement with the US Securities and Exchange Commission (SEC) in relation to the previously…
• 
  Story Nov 12, 2018 Discovery

  Artificial intelligence decodes cancer pathology images without image gallery

  Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.

• 
  Story Nov 12, 2018 Discovery

  Artificial intelligence decodes cancer pathology images

  Novartis researchers are collaborating with tech startup PathAI to search for hidden information in pathology slides.

• Press release Nov 11, 2018

  New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients

  Entresto® (sacubitril/valsartan) outperformed commonly used heart failure medicine enalapril in landmark study; delivered significantly greater and more rapid reductions in an established biomarker…
• 
  Story Nov 05, 2018 From Our Labs

  Women in Science: Wendy Winckler

  Meet Wendy Winckler, Executive Director of Oncology Research at Novartis.

• 
  Story Nov 05, 2018 From Our Labs

  Women in Science: Jennifer Allport-Anderson

  Cardiovascular researcher Jennifer Allport-Anderson describes the personal qualities and decisions that have made her a successful leader.